2nd Liquid Biopsy Surveillance and Early Detection Summit

Memo

Accelerating Patient Access to Early and Affordable Detection and Surveillance Tests The 2nd Liquid Biopsy Surveillance and Early Detection Summit returns as industry's only meeting showcasing biopharma-led case studies and assay developer technical progress to create a commercially viable path forward for non-invasive testing to support early disease pipeline progress. Ensure your whole team stays connected and ahead of the curve with unmatched industry insights across key challenges in scaling sensitive assays that enable earlier detection and utilizing ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options. Uniting patients, diagnostics and drug developers, this meeting is your one and only opportunity to learn about the latest advancements in liquid biopsy detection and early surveillance in oncology, neurology and rare disease, and how they can be implemented into clinical trials and in healthy populations. URLs:Tickets: https://go.evvnt.com/1851166-2?pid=5569 Brochure: https://go.evvnt.com/1851166-3?pid=5569  Date and Time: On Tue, 07 Nov 2023 09:00 - Thu, 09 Nov 2023 18:00 Venue Details: Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States Prices:Drug Developers and Academics Conference Pass: USD 0.50,Vendors Conference Pass: USD 3799.00 Speakers: Aadel Chaudhuri, Advisory Council, Washington University School of Medicine in St. Louis, Aleksandra Markovets, Director, Oncology Bioinformatics, AstraZeneca, Amanda Acerbi, Global Director, Precision Medicine, Janssen, Angela Silvestro, Director, Companion Diagnostics, GSK, David Yu, Director, Translational Sciences and Diagnostics, Bristol Myers Squibb, Feng Liu, Director, Translational Oncology, Pfizer, Gary Kelloff, Special Advisor, DCTD, National Cancer Institute, NIH, Lauren Leiman, Executive Director, BloodPAC, Liya Xu, Assistant Professor, Children's Hospital Los Angeles, Lorena Dieguez, Research Group Leader, INL - International Iberian Nanotechnology Laboratory, Maher Albitar, CEO/CMO, Genomic Testing Cooperative, Minakshi Guha, Associate Director, Precision Medicine and Companion Diagnostics, Takeda Pharmaceutical Co. Ltd., Mohan Bolisetty, Director, Biomarker and Diagnostics, WW Medical Oncology, Bristol Myers Squibb, Murat Karabacak, Instructor in Surgery, Massachusetts General Hospital (MGH) and Harvard Medical School, Phillip Galbo, Senior Translational, Research Scientist, Roswell Park Cancer Institute, Raluca Budiu-Predoiu, Director, Precision Medicine, Abbvie, Shadi Swaidani, Principle Scientist, Recursion Pharmaceuticals, Shou-Ching Jaminet, Co-Founder and Vice President of Discovery Science, Angiex, Steven Rosen, Visiting Scholar and Mentor, The Wyss Institute at Harvard University, Ying Li, CDx Lead, Takeda